Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335896 | 0.88 | ALDH1A1 (0.50) | MCL1ALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL30426642 | 0.88 | ALDH1A1 (0.50) | MCL1ALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL6738294 | 0.88 | SRC (0.49) | MCL1TPMTALDH1A1TSHRCYP2A6 | |
| SCHEMBL27426702 | 0.86 | TPMT (0.54) | MCL1TPMTALDH1A1HPGDTDP1 | |
| SCHEMBL5370373 | 0.83 | MCL1 (0.41) | MCL1TPMTALDH1A1TSHRCYP2A6 | |
| SCHEMBL2664413 | 0.82 | MCL1 (0.44) | MCL1TPMTALDH1A1TSHRHPGD | |
| SCHEMBL17518840 | 0.81 | ALDH1A1 (0.47) | MCL1ALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL5146420 | 0.79 | ALDH1A1 (0.55) | MCL1ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL9859402 | 0.77 | ALDH1A1 (0.43) | MCL1ALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL20570872 | 0.76 | MTNR1A (0.36) | MCL1TPMTALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2024102245-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2024-05-16 | — | — | WO | disclosed |
| US-8980933-B2 | Combretastatin analogs for use in the treatment of cancer | UNIVERSITAT BAYREUTH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2566851-B1 | Combretastatin analogs for use in the treatment of cancer | UNIVERSITÄT BAYREUTH (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-20130137740-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG | 2013-05-30 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2576514-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| EP-2566851-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | Universität Bayreuth (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011138409-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÄT BAYREUTH (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-7507851-B2 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS, A STATE CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507851-B2 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS, A STATE CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080119649-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2008-05-22 | — | — | US | disclosed |
| US-20070167412-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1802560-A2 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7223747-B2 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006036743-A2 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119649-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | TUBB3, TUBB8B, TUBB8 | MCL1 27/4885TPMT 1186/4885ALDH1A1 4790/4885 |
| US-20070167412-A1 | HALOCOMBSTATINS AND METHODS OF SYNTHESIS THEREOF | TUBB3, TUBB8B, TUBB8 | MCL1 27/4885TPMT 1186/4885ALDH1A1 4790/4885 |
| US-20130137740-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | ABCC1, ABCB1, HMGCR | MCL1 277/4885TPMT 376/4885ALDH1A1 1555/4885 |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | CHRM5, CHRM3, CHRNA3 | MCL1 3803/4885TPMT 1080/4885ALDH1A1 2558/4885 |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB, TUBB1 | MCL1 762/4885TPMT 370/4885ALDH1A1 2257/4885 |
| US-20050176688-A1 | Halocombstatins and methods of synthesis thereof | TUBB3, TUBB8B, TUBB8 | MCL1 27/4885TPMT 1186/4885ALDH1A1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.